Pulmonary hypertension

JAMA

Volumn 308, Issue 13, 2012, Pages 1366-1374

  Shah, Sanjiv J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; VASODILATOR AGENT;

AGED; BLOOD PRESSURE MEASUREMENT; CASE REPORT; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DYSPNEA; ECHOCARDIOGRAPH; FEMALE; HEART ATRIUM ENLARGEMENT; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERTENSION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LEG EDEMA; LEG SWELLING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART MURMUR; TRICUSPID VALVE REGURGITATION;

EID: 84866926572     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.12347     Document Type: Review

References (56)

1. Galiè N, Hoeper MM, Humbert M, et al ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2009;30(20):2493-2537.
2. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):S40-S47.
3. Simonneau G, Robbins IM, Beghetti M,et al.Updated clinical classification of pulmonary hypertension.J Am Coll Cardiol. 2009;54(1)(suppl):S43-S54.
4. McLaughlin VV, Archer SL, Badesch DB, et al ACCF/AHA.ACCF/AHA2009 expert consensus document on pulmonary hypertension. Circulation. 2009;119(16):2250- 2294.
5. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119(20):2663-2670.
6. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;53(13):1119-1126.
7. Pengo V, Lensing AW, Prins MH, et al Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257-2264.
8. Cuttica MJ, Kalhan R, Shlobin OA, et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med. 2010;104(12):1877-1882.
9. Strange G, Playford D, Stewart S, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort [published online July 3, 2012]. Heart. doi:10.1136/heartjnl-2012-301992.
10. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol. 2010;106(2):284-286.
11. Thenappan T, Shah SJ, Gomberg-Maitland M, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2011;4(3):257-265.
12. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1)(suppl):S55-S66.
13. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France. Am J Respir Crit Care Med. 2006;173(9):1023-1030.
14. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension. Eur Respir J. 2010;35(5):1079-1087.
15. Stone AC, Machan JT, Mazer J, Casserly B, Klinger JR. Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. Lung. 2011;189(3):207-212.
16. Minai OA, Ricaurte B, Kaw R, et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol. 2009;104(9):1300-1306.
17. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001;104(23):2797-2802. (Pubitemid 33126653)
18. Robbins IM, Newman JH, Johnson RF, et al. Association of the metabolic syndrome with pulmonary venous hypertension. Chest. 2009;136(1):31-36.
19. Farzaneh-Far R, Na B, Whooley MA, Schiller NB. Usefulness of noninvasive estimate of pulmonary vascular resistance to predict mortality, heart failure, and adverse cardiovascular events in patients with stable coronary artery disease (from the Heart and Soul Study).Am J Cardiol. 2008;101(6):762-766.
20. Ristow B, Ali S, Ren X, Whooley MA, Schiller NB. Elevated pulmonary artery pressure by Doppler echocardiography predicts hospitalization for heart failure and mortality in ambulatory stable coronary artery disease. J Am Coll Cardiol. 2007;49(1):43-49. (Pubitemid 46026900)
21. Abdelwhab S, Elshinnawy S. Pulmonary hypertension in chronic renal failure patients. Am J Nephrol. 2008;28(6):990-997.
22. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit. Circulation. 2009;120(11):992-1007.
23. Haddad F, Kudelko K, Mercier O, Vrtovec B, Zamanian RT, de Jesus Perez V. Pulmonary hypertension associatedwith left heart disease. Prog Cardiovasc Dis. 2011;54(2):154-167.
24. Guglin M, Khan H. Pulmonary hypertension in heart failure. J Card Fail. 2010;16(6):461-474.
25. Tryka AF, Godleski JJ, Schoen FJ, Vandevanter SH. Pulmonary vascular disease and hypertension after valve surgery for mitral stenosis. Hum Pathol. 1985;16(1):65-71. (Pubitemid 15158751)
26. Delgado JF, Conde E, Sánchez V, et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail. 2005;7(6):1011-1016. (Pubitemid 41443595)
27. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ.Right ventricular function in cardiovascular disease: part I. Circulation. 2008;117(11):1436-1448.
28. Haddad F, Doyle R, Murphy DJ,Hunt SA. Right ventricular function in cardiovascular disease: part II. Circulation. 2008;117(13):1717-1731.
29. van Wolferen SA, Marcus JT, Westerhof N, et al. Right coronary artery flow impairment in patients with pulmonary hypertension. Eur Heart J. 2008;29(1):120-127.
30. Gaine S. Pulmonary hypertension. JAMA. 2000;284(24):3160-3168. (Pubitemid 32039080)
31. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographicassessment of the right heart inadults. J Am Soc Echocardiogr. 2010;23(7):685-713.
32. Bland JM, Altman DG. Applying the right statistics. Ultrasound Obstet Gynecol. 2003;22(1):85-93.
33. Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension. Chest. 2011;139(5):988-993.
34. Testani JM, St John Sutton MG, Wiegers SE, Khera AV, Shannon RP, Kirkpatrick JN. Accuracy of non-invasively determinedpulmonaryartery systolic pressure. Am J Cardiol. 2010;105(8):1192-1197.
35. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615-621.
36. Giardini A. Limitations inherent to the simplified Bernoulli equation explain the inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension. Chest. 2011;140(1):270-271.
37. Machado RF, Gladwin MT. Pulmonary hypertension in hemolytic disorders. Chest. 2010;137(6)(suppl):30S-38S.
38. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895. (Pubitemid 38252536)
39. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011;365(1):44-53.
40. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J. 2012;39(1):112-118.
41. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle celldisease and pulmonary hypertension. JAMA. 2012;307(12):1254- 1256.
42. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034-1041. (Pubitemid 44684453)
43. Campo A, Mathai SC, LePavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182(2):252-260.
44. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patientswith primary pulmonary hypertension.Ann Intern Med. 1991;115(5):343-349.
45. Rich S, Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation. 2008;118(21):2190-2199.
46. Hoeper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;54(1)(suppl):S85-S96.
47. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular enddiastolic pressure. Chest. 2009;136(1):37-43.
48. Ryan JJ, Rich JD, Thiruvoipati T, Swamy R, Kim GH, Rich S. Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J. 2012;163(4):589-594.
49. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48(12):2546-2552. (Pubitemid 44881214)
50. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction. Circulation. 2011;124(2):164-174.
51. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50(22):2136-2144. (Pubitemid 350117342)
52. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115(1):59-66. (Pubitemid 46058612)
53. Anand I, McMurray J, Cohn JN, et al; EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH). Lancet. 2004;364(9431):347-354.
54. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure. Am Heart J. 1997;134(1):44-54.
55. Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation. 2008;117(19):2475-2483. (Pubitemid 351670454)
56. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265-272.